Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
NCT04893525

Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments

Led by University of British Columbia · Updated on 2025-06-08

658

Participants Needed

6

Research Sites

305 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a multi-centre, open-label RCT at four Emergency Departments (EDs) in British Columbia and Alberta. The purpose of the current study is to compare the effectiveness of buprenorphine/naloxone microdosing and standard dosing take-home induction regimens at enabling patients to successfully complete the induction regimen, and at retaining patients on opioid agonist therapy. We will randomize our enrolled patients to receive take-home microdosing or standard dosing packages of buprenorphine/naloxone. For the microdosing arm, patients immediately start taking low doses that increase to effective levels without requiring them to go into withdrawal. We hypothesize that ED patients provided buprenorphine/naloxone microdosing packages will be more likely to successfully complete the induction period compare to patients provided standard dosing packages. We furthermore hypothesize that those provided microdosing will be more likely to be retained in opioid agonist therapy, and will experience lower overdose, mortality, and healthcare utilization subsequent to their ED visit.

CONDITIONS

Official Title

Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged 18 years or older with opioid use disorder being discharged from the ED
  • Opioid use disorder defined as non-medical opioid use in the past 30 days and positive opioid dependency score on the Rapid Opioid Dependence Screen (RODS)
  • Clinical Opiate Withdrawal Scale (COWS) score less than or equal to 12 at ED assessment
  • Patients must be able to understand study procedures and interventions
Not Eligible

You will not qualify if you...

  • Active withdrawal at time of ED assessment with COWS score greater than 12
  • Hospital admission
  • Severe communication barriers preventing understanding of study procedures
  • Use of opioids for cancer or palliative care
  • Deemed unsafe to approach by ED providers
  • Incarceration
  • Not a resident of the province (British Columbia or Alberta) where care is sought
  • Currently receiving opioid agonist therapy with a prescription filled within 5 days before ED visit
  • Prior enrollment in the study
  • Known or suspected mechanical gastrointestinal obstruction or diseases affecting bowel transit
  • Suspected surgical abdomen
  • Severe respiratory insufficiency
  • Severe central nervous system depression, increased intracranial pressure, or head injury
  • Factors making home induction unsafe or requiring expert consultation, including allergy to buprenorphine/naloxone, severe respiratory or liver dysfunction, concurrent withdrawal or intoxication from sedatives, active prescription for sedative medications, use of monoamine oxidase inhibitors within 14 days, inability to safely store medications
  • Pregnancy (confirmed by urine pregnancy test in women of child-bearing age)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 6 locations

1

Foothills Medical Centre

Calgary, Alberta, Canada, T2N2T9

Actively Recruiting

2

Northeast Community Health Centre

Edmonton, Alberta, Canada, T5A 5E4

Actively Recruiting

3

Royal Alexandra Hospital

Edmonton, Alberta, Canada, T5H 3V9

Not Yet Recruiting

4

Vancouver General Hospital

Vancouver, British Columbia, Canada, V5Z 1M9

Actively Recruiting

5

University of British Columbia Hospital

Vancouver, British Columbia, Canada, V6T2B5

Actively Recruiting

6

St. Paul's Hospital

Vancouver, British Columbia, Canada, V6Z 1Y6

Actively Recruiting

Loading map...

Research Team

E

Elle Wang, MSc

CONTACT

C

Cindy Liu, BSc

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here